Peter Francis, BSc (Hons), BM, MD, PhD, FRCOphth, SVP Translational Research and Development at 4D Molecular Therapeutics (Emeryville, CA) is an ophthalmologist clinician-scientist with expertise in ophthalmic genetics and retinal disease. He graduated from medical school in the U.K. and undertook residency in London. He obtained his PhD in ophthalmic genetics from University College, London. Peter is fellowship trained in Retina, Genetics and Neurophthalmology. Over the past decade, he has been involved in translational retinal research and served as principal investigator on several important gene and stem-cell clinical trials. Previously, he was chief medical officer at RetroSense Therapeutics, a gene therapy company developing optogenetic therapy for eye disease, which was successfully purchased by Allergan.
Peter is a fellow of the Royal College of Ophthalmologists (London) and member of both The Macula and the American Ophthalmological societies. He has held academic faculty positions at St. Thomas’ Hospital, London, and most recently, Casey Eye Institute, Portland, OR. He has published about 100 peer-reviewed articles and received several awards, including “best up-and-coming medical researcher in the United Kingdom 2002” and technology and innovation awards from his prior university appointments. Peter has held numerous grants from NIH and from a variety of research foundations.